Skip to main content
16 Oct 2021
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab
Read More
8 Oct 2021
29 Sep 2021
New BIMZELX[®]▼ (bimekizumab) two-year data in moderate to severe plaque psoriasis presented at the 30th European Academy of Dermatology and Venereology (EADV) Congress
Read More
24 Sep 2021
10 Sep 2021
6 Sep 2021
BIMZELX[®]▼ (bimekizumab) Receives First Positive Health Technology Assessment Worldwide
Read More
3 Sep 2021
Transparency notification Wellington
Read More
3 Sep 2021
27 Aug 2021
27 Aug 2021
UCB showcases commitment to treatment and management of epilepsy at the 34th International Epilepsy Congress
Read More
Subscribe to
